A markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation

AAPS Journal

Volumn 15, Issue 4, 2013, Pages 1189-1199

  Sy, Sherwin K B ^a   Heuberger, Jules ^a   Shilbayeh, Sireen ^b   Conrado, Daniela J ^a   Derendorf, Hartmut ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b PRINCESS NOURAH BINT ABDULRAHMAN UNIVERSITY   (Saudi Arabia)

Author keywords

ABCB1; adverse events; CYP3A5; Markov; tacrolimus

Indexed keywords

AZATHIOPRINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ABCB1 GENE; ACUTE GRAFT REJECTION; ACUTE OTITIS MEDIA; ALLERGIC RASH; ANEMIA; ARTICLE; BACTERIAL INFECTION; CHICKENPOX; CHILD; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CONSTIPATION; CYP3A5 GENE; DEHYDRATION; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIARRHEA; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DYSPEPSIA; EYE DISEASE; FEMALE; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; GINGIVA DISEASE; GINGIVITIS; GRAFT FAILURE; GRAM NEGATIVE SEPSIS; GUM HYPERTROPHY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYDRONEPHROSIS; HYPERTENSION ENCEPHALOPATHY; HYPOKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOPENIA; MALE; MOUTH LESION; MYCOSIS; NEPHROTOXICITY; PERIPHERAL EDEMA; PERTHES DISEASE; PHENOTYPE; POPULATION RESEARCH; PROBABILITY; PRURITUS; PSYCHOSIS; PUFFY EYE; PYELONEPHRITIS; RESPIRATORY TRACT INFECTION; SKIN INFECTION; THORAX PAIN; THROMBOCYTOPENIA; TOOTH ABSCESS; URINARY TRACT INFECTION; VISUAL DISORDER; VOMITING;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP3A; FEMALE; GENE FREQUENCY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MARKOV CHAINS; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; TACROLIMUS; YOUNG ADULT;

EID: 84888012931     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-013-9528-9     Document Type: Article

References (48)

1. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623-53.
2. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II. Clin Pharmacokinet. 2010;49(4):207-21. doi: 10.2165/11317550-000000000-000001.
3. Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos. 2006;34(5):836-47. doi: 10.1124/dmd.105.008680.
4. Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P, et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant. 2003;3(4):477-83.
5. Zheng H, Zeevi A, Schuetz E, Lamba J, McCurry K, Griffith BP, et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol. 2004;44(2):135-40. doi: 10.1177/009127000326210844/2/135.
6. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation. 2003;76(8):1233-5. doi: 10.1097/01.TP.0000090753.99170.89.
7. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97(7):3473-8. doi: 10.1073/pnas.050585397050585397.
8. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002;359(9300):30-6. doi: 10.1016/S0140-6736(02)07276-8.
9. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet. 2010;49(3):141-75. doi: 10.2165/11317350-000000000-000001.
10. Hawwa AF, McKiernan PJ, Shields M, Millership JS, Collier PS, McElnay JC. Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Br J Clin Pharmacol. 2009;68(3):413-21. doi: 10.1111/j.1365-2125.2009.03461.x.
11. Herrlinger KR, Koc H, Winter S, Teml A, Stange EF, Fellermann K, et al. ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis. Clin Pharmacol Ther. 2011;89(3):422-8. doi: 10.1038/clpt.2010.348.
12. Choi JH, Lee YJ, Jang SB, Lee JE, Kim KH, Park K. Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. Br J Clin Pharmacol. 2007;64(2):185-91. doi: 10.1111/j.1365-2125.2007.02874.x.
13. Mai I, Perloff ES, Bauer S, Goldammer M, Johne A, Filler G, et al. MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol. 2004;58(5):548-53. doi: 10.1111/j.1365-2125.2004.02182.x.
14. Wang J, Zeevi A, McCurry K, Schuetz E, Zheng H, Iacono A, et al. Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A53/3 non-expressors. Transpl Immunol. 2006;15(3):235-40. doi: 10.1016/j.trim.2005.08.001.
15. MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant. 2004;4(6):914-9. doi: 10.1111/j.1600-6143.2004.00435.xAJT435.
16. Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87(6):721-6. doi: 10.1038/clpt.2010.17.
17. de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR. In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther. 2012;92(3):366-75. doi: 10.1038/clpt.2012.109.
18. Sy SK, Singh RP, Shilbayeh S, Zmeili R, Conrado D, Derendorf H. Influence of CYP3A5 6986A>G and ABCB1 3435C>T polymorphisms on adverse events associated with tacrolimus in Jordanian pediatric renal transplant patients. Clin Pharmacol Drug Dev. 2013;2(1):67-78. doi: 10.1002/cpdd.22.
19. Shilbayeh S, Hazza I. Pediatric renal transplantation in the Jordanian population: the clinical outcome measures during long-term follow-up period. Pediatr Neonatol. 2012;53(1):24-33. doi: 10.1016/j.pedneo.2011.11.006.
20. Bass RF. Stochastic processes. Cambridge: Cambridge University Press; 2011.
21. Lacroix BD, Lovern MR, Stockis A, Sargentini-Maier ML, Karlsson MO, Friberg LE. A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2009;86(4):387-95. doi: 10.1038/clpt.2009.136.
22. Ouellet D, Sutherland S, Wang T, Griffini P, Murthy V. First-time-in-human study with GSK1018921, a selective GlyT1 inhibitor: relationship between exposure and dizziness. Clin Pharmacol Ther. 2011;90(4):597-604. doi: 10.1038/clpt.2011.154.
23. Bizzotto R, Zamuner S, Mezzalana E, De Nicolao G, Gomeni R, Hooker AC, et al. Multinomial logistic functions in Markov chain models of sleep architecture: internal and external validation and covariate analysis. AAPS J. 2011;13(3):445-63. doi: 10.1208/s12248-011-9287-4.
24. Peng Z, Bao C, Zhao Y, Yi H, Xia L, Yu H, et al. Weighted Markov chains for forecasting and analysis in incidence of infectious diseases in Jiangsu Province, China. J Biomed Res. 2010;24(3):207-14. doi: 10.1016/S1674-8301(10) 60030-9.
25. Roy JN, Lajoie J, Zijenah LS, Barama A, Poirier C, Ward BJ, et al. CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab Dispos. 2005;33(7):884-7. doi: 10.1124/dmd.105.003822.
26. Bhatnagar V, Garcia EP, O'Connor DT, Brophy VH, Alcaraz J, Richard E, et al. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol. 2010;31(2):95-103. doi: 10.1159/000258688.
27. Rao DN, Manjula G, Sailaja K, Surekha D, Raghunadharao D, Rajappa S, et al. Association of CYP3A53 polymorphism with development of acute leukemia. Indian J Hum Genet. 2011;17(3):175-8. doi: 10.4103/0971-6866.92098.
28. Cho JH, Yoon YD, Park JY, Song EJ, Choi JY, Yoon SH, et al. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients. Transplant Proc. 2012;44(1):109-14. doi: 10.1016/j.transproceed. 2011.11.004.
29. Zhao W, Elie V, Roussey G, Brochard K, Niaudet P, Leroy V, et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009;86(6):609-18. doi: 10.1038/clpt.2009.210.
30. de Wildt SN, van Schaik RH, Soldin OP, Soldin SJ, Brojeni PY, van der Heiden IP, et al. The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation. Eur J Clin Pharmacol. 2011;67(12):1231-41. doi: 10.1007/s00228-011-1083-7.
31. Gijsen V, Mital S, van Schaik RH, Soldin OP, Soldin SJ, van der Heiden IP, et al. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J Heart Lung Transplant. 2011;30(12):1352-9. doi: 10.1016/j.healun.2011.08.001.
32. Kim JS, Aviles DH, Silverstein DM, Leblanc PL, Matti VV. Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant. 2005;9(2):162-9. doi: 10.1111/j.1399-3046.2005.00263.x.
33. Naesens M, Salvatierra O, Li L, Kambham N, Concepcion W, Sarwal M. Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients. Transplantation. 2008;85(8):1139-45. doi: 10.1097/TP.0b013e31816b431a.
34. Sy SK, Johnston JA, Class CF, Roberts EA, Kalow W, Tang BK. Mulitvariate cluster analysis of a human hepatic cytochrome P450 database. Eur J Clin Pharmacol. 2002;58(8):559-62.
35. Sy SK, Ciaccia A, Li W, Roberts EA, Okey A, Kalow W, et al. Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression. Eur J Clin Pharmacol. 2002;58(5):357-65. doi: 10.1007/s00228-002-0487-9.
36. Montini G, Ujka F, Varagnolo C, Ghio L, Ginevri F, Murer L, et al. The pharmacokinetics and immunosuppressive response of tacrolimus in paediatric renal transplant recipients. Pediatr Nephrol. 2006;21(5):719-24. doi: 10.1007/s00467-006-0014-9.
37. Yasuhara M, Hashida T, Toraguchi M, Hashimoto Y, Kimura M, Inui K, et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. Transplant Proc. 1995;27(1):1108-10.
38. Wallemacq PE, Furlan V, Moller A, Schafer A, Stadler P, Firdaous I, et al. Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. Eur J Drug Metab Pharmacokinet. 1998;23(3):367-70.
39. Hines RN. Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol. 2007;21(4):169-75.
40. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999;37(6):485-505.
41. Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, Tandler PJ, et al. Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther. 2003;307(2):573-82. doi: 10.1124/jpet.103.054841.
42. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27(4):383-91. doi: 10.1038/86882 86882.
43. Dally H, Bartsch H, Jager B, Edler L, Schmezer P, Spiegelhalder B, et al. Genotype relationships in the CYP3A locus in Caucasians. Cancer Lett. 2004;207(1):95-9. doi: 10.1016/j.canlet.2003.12.011.
44. Gervasini G, Vizcaino S, Gasiba C, Carrillo JA, Benitez J. Differences in CYP3A53 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations. Ther Drug Monit. 2005;27(6):819-21.
45. Sinues B, Vicente J, Fanlo A, Vasquez P, Medina JC, Mayayo E, et al. CYP3A53 and CYP3A41B allele distribution and genotype combinations: differences between Spaniards and Central Americans. Ther Drug Monit. 2007;29(4):412-6. doi: 10.1097/FTD.0b013e31811f390a.
46. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001;11(3):217-21.
47. Ostrovsky O, Nagler A, Korostishevsky M, Gazit E, Galski H. Genotype and allele frequencies of C3435T polymorphism of the MDR1 gene in various Jewish populations of Israel. Ther Drug Monit. 2004;26(6):679-84.
48. Santos PC, Soares RA, Santos DB, Nascimento RM, Coelho GL, Nicolau JC, et al. CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population. BMC Med Genet. 2011;12:13. doi: 10.1186/1471-2350-12-13.